Leishmania donovani infection down-regulates TLR2-stimulated IL-12p40 and activates IL-10 in cells of macrophage/monocytic lineage by modulating MAPK pathways through a contact-dependent mechanism.
The failure of Leishmania, an intracellular pathogen, to stimulate a pro-inflammatory response following entry into macrophages has been well reported. This occurs in spite of the fact that ligands for the toll-like receptors (TLR) have been recently shown on the parasite surface and their role in disease protection well documented. The outcome of infection in leishmaniasis is determined by the Th1 versus Th2 nature of the effector response and the generation of IL-12 and IL-10 by the infected macrophages is important for this decision. We evaluated the effect of L. donovani infection of monocytes (cell line THP-1, and monocytes derived from human peripheral blood) on Pam3cys (TLR2 ligand) and lipopolysaccharide (TLR4 ligand) stimulated production of IL-12p40 and IL-10. L. donovani infection caused suppression of TLR2 and TLR4-stimulated IL-12p40, with an increase in IL-10 production. Parasites also modulated the TLR2-stimulated mitogen-activated protein kinase (MAPK) pathway by suppressing MAPK P(38) phosphorylation and activating extracellular regulated kinase (ERK)1/2 phosphorylation. These effects could be reversed either by using a MAPK P(38) activator, anisomycin, or ERK1/2 inhibitor, U0126. L. donovani caused modulation of TLR2-stimulated MAPK pathways in a contact-dependent mechanism. In addition parasite structural integrity but not viability was required for suppression of TLR2-stimulated IL-12p40 and activation of IL-10. These observations suggest that L. donovani has evolved survival strategies that subvert the pro-inflammatory response generated through TLRs.
Chandra
Dinesh
D
Department of Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Raebareli Road, Lucknow, India.
Naik
Sita
S
D000818:Animals; D000841:Anisomycin / Q000494:pharmacology; D002070:Butadienes / Q000494:pharmacology; D002478:Cells, Cultured; D004305:Dose-Response Relationship, Drug; D015536:Down-Regulation / Q000276:immunology; D004791:Enzyme Inhibitors / Q000494:pharmacology; D006801:Humans; D016753:Interleukin-10 / Q000096:biosynthesis*; D053762:Interleukin-12 Subunit p40 / Q000096:biosynthesis*; D007893:Leishmania donovani; D007898:Leishmaniasis, Visceral / Q000276:immunology*; D020935:MAP Kinase Signaling System / Q000187:drug effects / Q000276:immunology; D009000:Monocytes / Q000276:immunology; D009570:Nitriles / Q000494:pharmacology; D010766:Phosphorylation / Q000187:drug effects; D012333:RNA, Messenger / Q000235:genetics; D020133:Reverse Transcriptase Polymerase Chain Reaction / Q000379:methods; D051195:Toll-Like Receptor 2 / Q000096:biosynthesis / Q000235:genetics / Q000276:immunology*; D051197:Toll-Like Receptor 4 / Q000096:biosynthesis / Q000235:genetics
D002070:Butadienes; D004791:Enzyme Inhibitors; D053762:Interleukin-12 Subunit p40; D009570:Nitriles; D012333:RNA, Messenger; C495342:TLR2 protein, human; C495345:TLR4 protein, human; D051195:Toll-Like Receptor 2; D051197:Toll-Like Receptor 4; C113580:U 0126; D016753:Interleukin-10; D000841:Anisomycin
J Leukoc Biol. 2004 May;75(5):749-55
15075354
J Immunol. 2004 Sep 1;173(5):3297-304
15322192
J Immunol. 1995 May 1;154(9):4623-9
7722314
J Immunol. 2006 Jul 15;177(2):1282-8
16818788
Immunol Lett. 2005 Jun 15;99(1):17-23
15894106
J Immunol. 2001 Jan 15;166(2):1141-7
11145695
J Immunol. 2007 Jan 15;178(2):1077-85
17202371
Cytokine. 2000 Aug;12(8):1228-31
10930301
Curr Opin Immunol. 2003 Feb;15(1):5-11
12495726
Mol Cell. 1998 Aug;2(2):253-8
9734363
J Leukoc Biol. 2007 May;81(5):1188-96
17261547
EMBO J. 1999 Apr 1;18(7):1845-57
10202148
Microbes Infect. 2002 Jul;4(8):763-71
12270723
J Exp Med. 1994 Feb 1;179(2):447-56
7905017
Infect Immun. 2004 Apr;72(4):1920-8
15039311
Eur J Immunol. 2006 Feb;36(2):411-20
16369915
Cell Microbiol. 2007 Jan;9(1):84-96
16889626
Infect Immun. 2002 Dec;70(12):6828-38
12438359
Infect Immun. 2002 Sep;70(9):5026-35
12183549
J Immunol. 2003 Nov 1;171(9):4552-60
14568928
Nat Med. 2004 May;10(5):540-4
15107845
Annu Rev Immunol. 2002;20:197-216
11861602
Indian J Med Res. 2006 Mar;123(3):331-44
16778314
Eur J Immunol. 2003 Oct;33(10):2822-31
14515266
J Immunol. 1999 Dec 15;163(12):6403-12
10586030
J Exp Med. 1996 Feb 1;183(2):515-26
8627163
Eur J Immunol. 1998 Aug;28(8):2467-77
9710224
J Exp Med. 1997 Jun 2;185(11):1987-95
9166428
J Exp Med. 1998 Jun 15;187(12):2097-101
9625770
Mol Biochem Parasitol. 2003 Aug 31;130(2):65-74
12946842
Mol Cell Biochem. 1996 Jan 12;154(1):23-9
8717413
Trends Immunol. 2003 Jul;24(7):358-63
12860525
Clin Exp Immunol. 2005 Apr;140(1):149-56
15762886
Eur J Immunol. 1998 Apr;28(4):1389-400
9565379
Eur J Immunol. 2001 Mar;31(3):876-83
11241293
J Exp Med. 2003 Apr 21;197(8):1037-43
12695487
J Immunol. 2004 Apr 15;172(8):4902-6
15067069
J Exp Med. 1997 Jun 2;185(11):1977-85
9166427
J Immunol. 2003 Apr 15;170(8):4237-41
12682257
Mol Biochem Parasitol. 1999 Jul 30;102(1):1-12
10477171
Nature. 2002 Apr 18;416(6882):750-6
11923871
J Infect Dis. 1996 Jun;173(6):1515-8
8648233
Curr Drug Targets Immune Endocr Metabol Disord. 2002 Oct;2(3):201-26
12476486
Immunol Res. 2006;34(1):33-48
16720897
Eur J Immunol. 2000 Aug;30(8):2235-44
10940915
J Biol Chem. 1999 Feb 26;274(9):5835-42
10026206